TITLE

Qiagen offers $101 million for 47% stake in Ipsogen

PUB. DATE
June 2011
SOURCE
Medical Device Daily;6/17/2011, Vol. 15 Issue 112, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article focuses on the plan of Qiagen to acquire a 47% stake in Ipsogen. The acquisition deal, valued at 101 million U.S. dollars, would provide Qiagen access to wide range of assays covering several biomakers. According to Peer Schatz of Qiagen, the deal would further expand the company's global leadership in molecular assays for profiling and personalized healthcare. In 2010, Ipsogen posted a 24% net sales growth to 11 million U.S. dollars.
ACCESSION #
61869609

 

Related Articles

  • Qiagen buys 61% of Ipsogen, beefs up its Cellestis offer.  // Medical Device Daily;7/12/2011, Vol. 15 Issue 128, p2 

    The article reports on the acquisition by Qiagen of 61% of Ipsogen, a developer of molecular profiling and personalized healthcare diagnostics for a wide range of applications in the hematology field.

  • Qiagen acquires AmniSure, accesses pregnancy assay.  // Medical Device Daily;5/7/2012, Vol. 16 Issue 88, p2 

    The article reports on the acquisition by Qiagen of AmniSure International, a firm that produces an assay for determining whether a pregnant woman is suffering rupture of fetal membranes (ROM). For 2012, the transaction is expected by Qiagen to contribute 12 million U.S. dollars to the firm and...

  • Deals roundup.  // Medical Device Daily;10/1/2009, Vol. 13 Issue 189, p7 

    The article reports on the acquisition of DxS, a privately-held developer and manufacturer of companion diagnostic products, by Qiagen. With the acquisition, Qiagen believes it has taken a strong leadership position in the personalized health care. According to Qiagen, the combined company is...

  • QIAGEN Completes Acquisition of Cellestis Limited.  // Worldwide Biotech;Oct2011, Vol. 23 Issue 10, p4 

    The article reports on the acquisition by Qiagen of Cellestis Limited. According to Peter M. Schiatz of Qiagen, the integration process will be started after completing the transaction. Information on the QuantiFERON® technology of Cellestis is presented. Qiagen is a holding company based in...

  • Comerica Inc. acquires Sterling. Robertson, Rob // Fort Worth Business Press;1/24/2011, Vol. 23 Issue 4, p1 

    The article reports that Comerica Inc. has acquired Houston, Texas-based Sterling Bancshares Inc. in a 1 billion U.S. dollar all-stock deal. Comerica's Texas market president Pat Faubion notes that the deposit base of Sterling will give Comerica more leverage to market its products through a...

  • Novatek, Gazprom Neft buying Eni stake in SeverEnergia for $2.9 bln (Part 2). Interfax // Russia & CIS Business & Financial Newswire;11/20/2013, p1 

    MOSCOW. Nov 20 (Interfax) - Yamal Development, a 50/50 joint venture between Novatek (MOEX: NVTK) and Gazprom Neft (MOEX: SIBN), have signed a binding agreement with the Italian energy company, Eni on acquiring a 60% equity stake in Arctic Russia B.V., which owns 49% of the SeverEnergia Joint...

  • Qiagen completes Digene buy; ME buys stroke treatment rights.  // Medical Device Daily;8/1/2007, Vol. 11 Issue 145, p2 

    The article reports on the completion of the acquisition of Digene by Qiagen of the Netherlands. Report says that Qiagen has completed the acquisition through a tender offer and subsequent merger of Digene with and into a wholly owned subsidiary of the company. Under the deal, Digene will become...

  • Qiagen's shareholders okay $1.6 billion merger with Digene.  // Medical Device Daily;7/23/2007, Vol. 11, p6 

    The article announced that Qiagen has received the vote of the necessary percentage of its shareholders in favor of the $1.6 billion acquisition of Digene at its extraordinary general meeting of shareholders held in the Netherlands. The companies reported that they had entered into a merger...

  • Rapigene bargain buy for Qiagen. Hodgson, John // Nature Biotechnology;Feb2000, Vol. 18 Issue 2, p132 

    Reports on the acquisition of the genomic analysis company Rapigene by the biotechnology company Qiagen NV. Factors which led to the acquisition of the genomic analysis company; Owner of Rapigene prior to the acquisition.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics